Health News Releases

  • Today May 21
January 05, 2016 13:30
NOW PUBLISHED IN THE ANNALS OF SURGERY: LONG-TERM FAVORABLE RESULTS DEMONSTRATE GORE BIO-A TISSUE REINFORCEMENT EFFICACY IN COMPLEX VENTRAL HERNIA REPAIRS
W. L. Gore & Associates, Inc. (Gore) today announced final results of a long-term, prospective, multicenter study[1] evaluating the use of GORE® BIO-A® Tissue Reinforcement, a biosynthetic mesh, in co
January 05, 2016 10:20
Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer
Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal an
January 04, 2016 22:00
Cellular Regenerative Therapy Greeted by French Minister of Health
After European authorization was obtained this summer, the French and British regulatory agencies have authorized CellProthera to begin its first phase I/IIB clinical trial in Humans, starting January
January 04, 2016 13:30
Herbalife Appoints Filipino Doctor to Its Nutrition Advisory Board
Global nutrition company, Herbalife welcomes Dr. Francis Gregory Samonte, an expert in pediatric neurology, to become the first Filipino appointed to its prestigious Nutrition Advisory Board (NAB), ef
December 28, 2015 14:00
Takeda Provides Further Information about Its New Business Venture with Teva
Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement regarding the overview of their new bu
December 23, 2015 10:55
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the research-driven pharmaceutical company will establish a new large-scale
December 23, 2015 10:30
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Merck and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with plat
December 21, 2015 19:15
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (
December 21, 2015 15:45
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been grante
December 21, 2015 11:50
Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore (http://goo.gl/7U6Olz), 18-21 December 2015. New dat
December 18, 2015 18:20
Retired U.S. Senator Tom Harkin Joins Masimo’s Board of Directors
Masimo (www.masimo.com) (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, announced today that retired Senator Tom Harkin, former five-term U.S. Senator and former Cha
December 17, 2015 13:45
First Patients Enrolled in the Gore RELINE MAX Clinical Study
W. L. Gore & Associates (Gore) (www.goremedical.com) announces that the first patients are now enrolled in the Gore RELINE MAX Clinical Study, a post-approval study to continue to evaluate the GORE® V
December 17, 2015 13:30
Takeda Announces Sale of Respiratory Portfolio to AstraZeneca
Takeda Pharmaceutical Company Limited (TOKYO:4502, http://goo.gl/eX9kbP) today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Taked
December 16, 2015 13:00
President Clinton To Deliver Keynote Remarks at the 4th Annual World Patient Safety, Science & Technology Summit
The Patient Safety Movement Foundation (http://patientsafetymovement.org) announced today that President Bill Clinton, Founder of the Clinton Foundation & 42nd President of the United States, will del
December 15, 2015 21:00
Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Sanofi (http://en.sanofi.com)and Boehringer Ingelheim (www.boehringer-ingelheim.com) today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transa
December 15, 2015 20:00
WIN 2016 Symposium June 27-28, Paris: “Innovative Approaches to Improve Cancer Patient Outcomes”
WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to ad
December 15, 2015 17:40
Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the Shonan Research Center (T-CiRA)
The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint research program to develop c
December 15, 2015 17:10
Spain’s SENSAR Makes a Commitment to the Patient Safety Movement Foundation
The Patient Safety Movement Foundation (http://patientsafetymovement.org) announced today a commitment from Spain’s anesthesia national incident reporting system, Sistema Español de Notificacion en Se
December 15, 2015 14:50
Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF
Boehringer Ingelheim today announces the initiation of trial 1199.222 (ClinicalTrials.gov Identifier: NCT02579603), a new 12 week study to assess the safety, tolerability and pharmacokinetics of add-o
December 11, 2015 13:55
Quintiles Launches Suite of Services to Integrate Asset Development Planning
Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines developm
December 10, 2015 13:55
Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/g
December 09, 2015 10:00
New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS) study. The global Phase III trial, which is now o
December 08, 2015 16:20
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases
Takeda Pharmaceutical Company Limited (TOKYO:4502, http://goo.gl/eX9kbP) and Cour Pharmaceutical Development Company, Inc. today announced a partnership to research and develop novel immune modulating
December 07, 2015 17:50
Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society
December 07, 2015 15:10
Takeda Reports Five-Year Overall Survival Data for ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) announced post-treatment follow up data from the pivotal phase 2 study of single-agent brentuximab vedotin for the treatment of r
25 per page50 per page75 per page100 per page